Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 66 | Vintage Vibes

CPI Card Group’s Quiet Cash Machine Faces a Digital Reality Check

CPI Card Group stock shows strong cash flow and revenue growth, but acquisition costs, tariffs, and digital payment trends raise long-term questions.

2 ETFs to Play Both Sides of the Iran War Ceasefire

2 ETFs to Play Both Sides of the Iran War Ceasefire

ETFs focused on oil and air travel are two potential plays for different outcomes of the war between the United States and Iran.

Qualcomm’s 50% Surge: Bubble Territory or Breakout Moment?

Qualcomm’s 50% Surge: Bubble Territory or Breakout Moment?

Qualcomm looks technically stretched, but with a new growth story taking shape, this rally should still have room to run.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Powering Up: UGI Banks $685M in Strategic Turnaround

UGI Corporation is divesting non-core assets to strengthen its balance sheet and sharpen its focus on its primary natural gas and propane distribution.

3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

ETFs focused on emerging markets can give concentrated exposure to fast-growing markets at a time when the U.S. economy's growth prospects may falter.

Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook

Roblox shares fall to a new low after lowering guidance tied to safety changes. Softer user trends and margin pressure are weighing on sentiment.

2 Stocks to Watch as the Quantum Space Gets More Crowded

A new product from Cisco and the anticipated IPO of Honeywell's Quantinuum are two of the latest factors complicating the landscape for existing quantum firms.

inkl

Read news from The Economist, FT, and more,
with one subscription

Trump’s Rescheduling of Marijuana Is a Spark for Top Marijuana ETFs

Trump’s Rescheduling of Marijuana Is a Spark for Top Marijuana ETFs

Trump’s move to reschedule marijuana has sparked a cannabis stock rally. Despite past losses, ETFs like MJ and MSOS offer a speculative buy-low opportunity.

Q1 2026 Telecom Wars: Analyst Eye 30% Gains in T-Mobile Post-Earnings

Q1 2026 Telecom Wars: Analyst Eye 30% Gains in T-Mobile Post-Earnings

Telecom giants reported solid results in Q1 2026. Analysts are particularly bullish on T-Mobile going forward, projecting over 30% upside.

Wall Street Loves TJX, But Is the Stock Still a Good Deal for Investors?

Wall Street Loves TJX, But Is the Stock Still a Good Deal for Investors?

TJX stock has surged on consistent earnings beats and strong demand, but with growth expected to moderate, investors are weighing how much upside remains.

The AI Supercycle's Most Undervalued Manufacturer

The AI Supercycle's Most Undervalued Manufacturer

Sanmina Corporation's strategic pivot into AI data center hardware manufacturing is driving triple-digit revenue growth and signaling a major valuation reset.

The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

Dylan Jovine of Behind the Markets identifies five chip stocks set to benefit from the SpaceX IPO and the agentic AI wave driving it.

Visa Soars Post-Earnings; Outlook Positive Despite AI Risks

Visa Soars Post-Earnings; Outlook Positive Despite AI Risks

Visa's latest earnings were a big win for shares. Despite macro and AI fears, Visa powered ahead, posting its highest growth since 2022.

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

Get all your
news in one place.

100's of premium titles.
One news app.

These 3 AI Stocks Just Crushed Earnings: Still Time To Buy?

STX, SIMO, and NXPI each surged after strong Q1 2026 earnings, but valuations and overbought technicals raise questions about remaining upside for each stock.

After 15% L3Harris Price Drop, Is It Time to Buy or Time to Fly?

L3Harris is positioned to rebound and hit fresh highs but a lower low may come before it begins. Growth, margin, and market sentiment drive the action.

MarketBeat Week in Review – 04/27 - 05/01

Sell in May and go away may not be the right strategy after stocks closed out a strong April and strong earnings point to more gains

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

Get all your
news in one place.

100's of premium titles.
One news app.

SanDisk Earnings Crush Estimates With 251% Revenue Surge

SNDK's Q3 revenue of $5.95 billion surged 251% YOY, with non-GAAP EPS crushing the $14.36 consensus by 63%, while Q4 sales and EPS guidance topped estimates by a wide margin.

MaxLinear’s Explosive 200% Rally Looks Impressive—But Can It Last?

MaxLinear surged 80% after Q1 2026 earnings on strong data center growth, but negative net margins and a forward P/E of 60 raise valuation concerns.

5 Reasons Rambus Stock Price Collapse Is One Hot Entry Point

Rambus is amid a shift from IP sales and licensing to product sales and it is paying off as AI demand supports growth and wider margins.

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside

Bed Bath & Back to Life? An Aggressive Turnaround Takes Shape

With its first revenue increase in nineteen quarters, Bed Bath & Beyond is aggressively executing a strategic pivot toward a unified home services model.

Apple’s Earnings Make $300 Look Like a Matter of When, Not If

Apple’s earnings reinforced its bullish outlook, and a move back towards $300 is starting to look increasingly likely in the coming weeks.

Sherwin-Williams: The Boring Beauty Play on Housing Recovery

Sherwin-Williams stock dips after earnings, but its long-term outlook as a housing recovery play and dividend compounder remains intact

1 … 65 66 67 68

People

202,375 stories

Jeffrey Neal Johnson

Jennifer Ryan Woods

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

International Monetary Fund

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Emerging Markets

Places

397,753 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play